Floatz logo

Fludarabine

BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Autologous Cd33/Cll1 Dual-Target Car-T Module
Beijing Biotech
Phase 1/2CC
Autologous Cd19/Cd22 Dual-Target Car-T Module
Beijing Biotech
Phase 1/2CC
Autologous Cd19/Cd20 Dual-Target Car-T Module
Beijing Biotech
Phase 1/2CC
Autologous Bcma/Cd38 Dual-Target Car-T Module
Beijing Biotech
Phase 1/2CC
Autologous Cd33/Cd123 Dual-Target Car-T Module
Beijing Biotech
Phase 1/2CC
Autologous Cd5/Cd7 Dual-Target Car-T Module
Beijing Biotech
Phase 1/2CC
Autologous Bcma/Gprc5D Dual-Target Car-T
Beijing Biotech
Phase 1/2CC
Autologous Bcma/Cd19 Dual-Target Car-T Module
Beijing Biotech
Phase 1/2CC

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →